Cubist's Cubicin Approval Expanded

The Food and Drug Administration expanded its approval of Cubist Pharmaceuticals Inc.'s (CBST) Cubicin to treat Staph infections in the bloodstream. Shares of Cubist leaped $4.30 to close at $25.55.